Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure-Reference-Cited by-同舟云学术

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure

Published:2014-04 Issue:4 Volume:38 Page:443-446
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Jaglal Michael V.,Duong Vu H.,Bello Celeste M.,Al Ali Najla H.,Padron Eric,Fernandez Hugo F.,List Alan F.,Lancet Jeffrey E.,Komrokji Rami S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. Azacitidine for the treatment of patients with acute myeloid leukemia with 20–30% blasts and multilineage dysplasia;Font;Adv Ther,2011

3. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

4. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome;Kantarjian;Cancer,2006

5. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome;Gajewski;J Clin Oncol,1989

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis;Medicine;2023-11-03

2. A case of high‐risk AML in a patient with advanced systemic mastocytosis;Clinical Case Reports;2023-07

3. Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents;Leukemia & Lymphoma;2023-03-08

4. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms;Leukemia;2022-12-12

5. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia;Blood;2021-09-20